MedPath
HSA Product

RINALIX TABLET 2.5 mg

Product approved by Health Sciences Authority (SG)

Basic Information

RINALIX TABLET 2.5 mg

TABLET, FILM COATED

Regulatory Information

SIN11664P

September 13, 2001

Prescription Only

Therapeutic

ORAL

August 10, 2023

June 3, 2025

XC03BA11

Company Information

APEX PHARMA MARKETING PTE. LTD.

APEX PHARMA MARKETING PTE. LTD.

Active Ingredients

INDAPAMIDE

Strength: 2.5 mg

Detailed Information

Contraindications

**Contraindications** Anuria, stroke, recent cerebrovascular accident, severe hepatic insufficiency, known hypersensitivity to indapamide or to other sulfonamide-derived drugs.

Indication Information

**Indications** Rinalix is indicated for the treatment of essential hypertension, alone or in combination with other antihypertensive drugs.

© Copyright 2025. All Rights Reserved by MedPath